<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789867</url>
  </required_header>
  <id_info>
    <org_study_id>cro851</org_study_id>
    <secondary_id>Version 3 08.09.08</secondary_id>
    <nct_id>NCT00789867</nct_id>
  </id_info>
  <brief_title>Single Dose of pGM169/GL67A in CF Patients</brief_title>
  <official_title>Evaluation of Safety and Gene Expression With a Single Dose of pGM169/GL67A Administered to the Nose and Lung of Individuals With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objectives are to assess safety, tolerability and gene expression after a single
      dose of non-viral CFTR gene therapy (pGM169/GL67A) administered to the nose and lungs of
      patients with cystic fibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: examination, oximetry, spirometry, clinical blood samples, chest CT, gas transfer Expression: transgene mRNA and CFTR protein expression; potential difference measurements in nose and bronchi, sputum inflammatory markers</measure>
    <time_frame>Days 2,6,15,28 post-treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>pGM169/GL67A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single nebulised and nasal dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pGM169/GL67A</intervention_name>
    <description>Plasmid expressing the human CFTR gene complexed with cationic lipid 67 and helper lipids: 10 ml nebulised and 1 ml nasal administration (n=3) and 20 ml nebulised and 2 ml nasal (n=24)</description>
    <arm_group_label>pGM169/GL67A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cystic fibrosis confirmed by sweat testing or genetic analysis

          -  Males and females aged 16 years and above

          -  Forced expiratory volume in the 1st second (FEV1) &gt; 60% predicted values

          -  Clinical stability at entry

          -  Prepared to take effective contraceptive precautions for the duration of their
             participation in the study and for 3 months thereafter

          -  If taking regular rhDNase (pulmozyme) is willing, and considered able by independent
             medical carers, to withhold treatment for 24 hours before and 24 hours after the gene
             therapy dose

          -  Written informed consent obtained

          -  Permission to inform GP of participation in study

        Exclusion Criteria:

          -  Infection with Burkholderia cepacia complex organisms or MRSA

          -  Significant nasal pathology including polyps, clinically-significant rhinosinusitis,
             or recurrent severe epistaxis (nose bleeds)

          -  Acute upper respiratory tract infection within the last 2 weeks

          -  Previous spontaneous pneumothorax without pleurodesis

          -  Recurrent severe haemoptysis

          -  Current smoker

          -  Significant comorbidity including:

               1. Moderate/severe CF liver disease

               2. Significant renal impairment

               3. Significant coagulopathy

          -  Receiving 2nd line immunosuppressant drugs such as methotrexate, cyclosporine,
             intravenous immunoglobulin preparations

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Alton</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane C Davies</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uta Griesenbach</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Hyde</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah Gill</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Porteous</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edinburgh University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Boyd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edinburgh University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alastair Innes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edinburgh University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.cfgenetherapy.org.uk/</url>
    <description>UK CF Gene Therapy Consortium website</description>
  </link>
  <reference>
    <citation>Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG, Hodson ME, Durham SR, Li D, Jeffery PK, Scallan M, Balfour R, Eastman SJ, Cheng SH, Smith AE, Meeker D, Geddes DM. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 1999 Mar 20;353(9157):947-54.</citation>
    <PMID>10459902</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single dose</keyword>
  <keyword>Pilot</keyword>
  <keyword>Safety</keyword>
  <keyword>Gene expression</keyword>
  <keyword>Tolerability</keyword>
  <keyword>CFTR gene</keyword>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Non-viral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

